Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer

@article{Weiss2019SacituzumabGB,
  title={Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer},
  author={Jennifer A Weiss and Ashley E. Glode and Wells A. Messersmith and Jennifer R. Diamond},
  journal={Expert Review of Anticancer Therapy},
  year={2019},
  volume={19},
  pages={673 - 679}
}
ABSTRACT Introduction: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype associated with an increased risk of recurrence and cancer-related death. Unlike hormone receptor-positive or HER2-positive breast cancers, there are limited targeted therapies available to treat TNBC and cytotoxic chemotherapy remains the mainstay of treatment. Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate targeting Trop-2 expressing cells and selectively delivering SN-38, an… 
Tackling metastatic triple-negative breast cancer with sacituzumab govitecan
TLDR
Sacituzumab govitecan has promising survival benefits in patients with previously treated mTNBC based on data from the ASCENT trial, and is being evaluated in HR-positive breast cancers.
Sacituzumab govitecan: a new antibody-drug conjugates in the cancer treatment landscape
: Cancer is the leading cause of death around whole world, has a high incidence rate and a high fatality rate, accounting for millions of deaths in recent years. Metastatic tumour spreads to other
Bio-Inspired and Smart Nanoparticles for Triple Negative Breast Cancer Microenvironment
TLDR
Intensive efforts have been made for exploring cell-membrane coated nanoparticles and immune cell-targeted nanoparticles (immunotherapy) to modulate the tumor microenvironment and deliver accurate amounts of therapeutic agents to TNBC without stimulating the immune system.
Applications of Extracellular Vesicles in Triple-Negative Breast Cancer
TLDR
The most recent applications of EVs in TNBC as diagnostic/prognostic biomarkers, nanoscale drug delivery systems and immunotherapeutic agents, as well as the associated challenges and future directions of EV applications in cancer immunotherapy are presented.
A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors
TLDR
This work reviews the available literature concerning Sacituzumab govitecan, with a focus on its toxicity spectrum and possible biomarkers of its response, and finds Trop-2 overexpression and the presence of BRCA1/2 mutations seem to be the most promising.
The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials
TLDR
The use of novel agents matched with biomarkers to identify patients with the best chance of sustainable response offers new hope and there is great potential for improving the outcomes for patients with TNBC.
Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors
TLDR
Current advancements in the medical management of brain metastases can be categorized into targeted therapies, methods of overcoming treatment resistance, novel combinations of therapies, and modulation of the tumor microenvironment with a specific focus on immunotherapy.
TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer
TLDR
It is demonstrated that TROP2 could serve as a patient-tailoring and predictive biomarker for ADC therapeutics but not as a general prognostic biomarker to predicate patient survival.
Radiomics in Triple Negative Breast Cancer: New Horizons in an Aggressive Subtype of the Disease
TLDR
The variation of some radiomics features in the neoadjuvant settings provides a tool for the rapid evaluation of treatment efficacy and can generate complex predictive and prognostic models.
...
1
2
...

References

SHOWING 1-10 OF 48 REFERENCES
Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer
TLDR
It is shown that sacituzumab govitecan‐hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple‐negative breast cancer and was also associated with clinical benefit rate and overall survival.
Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies
TLDR
This review summarizes the clinical efficacy, perspectives and future challenges of using new treatment options for metastatic TNBC, such as poly‐ADP‐ribose‐polymerase inhibitors, antiandrogen therapies and immune checkpoint inhibitors (antiprogrammed death receptor‐1/PD‐L1 monoclonal antibodies).
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
  • T. Traina, K. Miller, J. Cortés
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2018
TLDR
This phase II study evaluated the antitumor activity and safety of enzalutamide in patients with locally advanced or metastatic AR-positive TNBC and demonstrated clinical activity and was well tolerated in Patients with advanced AR- positive TNBC.
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer
TLDR
The standard systemic and future treatment options in mTNBC are evaluated, including targeted therapy and immunotherapy, and select synergistic combinations can produce faster and more significant response rates compared with monotherapy.
An overview of triple-negative breast cancer
TLDR
Important molecular characteristics have been identified that can subdivide this group of breast cancers further and can provide alternative systemic therapies and reliable predictive biomarkers and newer drugs against the known molecular pathways are required.
Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer
TLDR
Atezolizumab plus nab‐paclitaxel prolonged progression‐free survival among patients with metastatic triple‐negative breast cancer in both the intention‐to‐treat population and the PD‐L1–positive subgroup.
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
  • A. Bardia, I. Mayer, L. Vahdat
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2017
TLDR
Sacituzumab govitecan was well tolerated and induced early and durable responses in heavily pretreated patients with metastatic TNBC, and Trop-2 warrants further research.
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.
TLDR
This work seeks to review the most recent efforts to classify TNBC based on the comprehensive profiling of tumors for cellular composition and molecular features to help improve risk stratification of patients, guide treatment decisions and surveillance, and help identify new targets for drug development.
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
TLDR
Pre-clinical data is provided that could inform clinical trials designed to test the hypothesis that improved outcomes can be achieved for TNBC patients, if selection and combination of existing chemotherapies is directed by knowledge of molecular TNBC subtypes.
Breast Cancer Immunotherapy: Facts and Hopes
  • L. Emens
  • Medicine, Biology
    Clinical Cancer Research
  • 2017
TLDR
Smart clinical trials testing rational immunotherapy combinations that include robust biomarker evaluations will accelerate clinical progress, moving us closer to effective immunotherapy for almost all patients with breast cancer.
...
1
2
3
4
5
...